搜尋結果
MIMS home. Drugs. Info. Slo-Theo. theophylline. Manufacturer: Ethypharm Industries. Distributor: Primal. Concise Prescribing Info. Contents. Theophylline. Indications/Uses. Continuous symptomatic treatment of persistent asthma & of other forms of COPD. Dosage/Direction for Use. Adult Initially 5-8 mg/kg/day. Usual effective dose: 7-12 mg/kg/day.
Gout 80 mg once daily. May consider 120 mg once daily if serum uric acid is >6 mg/dL (357 micromole/L) after 2-4 wk. Patient w/ mild hepatic impairment 80 mg. TLS 120 mg once daily. Start 2 days before the beginning of cytotoxic therapy & continue for a min of 7 days. May be prolonged up to 9 days according to chemotherapy duration.
Amlorine 10 tab 10 mg. amlodipine besilate. Packing/Price. 3 × 10's. MIMS Class. Anti-Anginal Drugs, Calcium Antagonists. ATC Classification. C08CA01 - amlodipine : Belongs to the class of dihydropyridine derivative selective calcium-channel blockers with mainly vascular effects. Used in the treatment of cardiovascular diseases.
Sanofi Hong Kong is part of Sanofi, a global and diversified healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: Diabetes Solutions, Human Vaccines, Innovative Drugs, Rare Diseases, Consumer Healthcare, Emerging ...
Concise Prescribing Info. Contents. Per 5 mL Dextromethorphan HBr 10 mg, chlorpheniramine maleate 1 mg. Indications/Uses. Cough in cold, flu, TB, bronchitis, bronchial asthma, pertussis, measles, pneumonia, excessive smoking, psychogenic cough. Dosage/Direction for Use. Adult 1-2 tsp. Childn ≥6 yr ½-1 tsp. To be taken tds-qds. Administration.
MIMS home. Drugs. Info. Montelukast Actavis. montelukast. Manufacturer: Teva. Distributor: Zuellig. Concise Prescribing Info. Contents. Montelukast. Indications/Uses. Treatment of asthma as add-on therapy in patients w/ mild to moderate persistent asthma inadequately controlled on inhaled corticosteroids & short-acting β-agonists.
2021年3月9日 · Haematologists from the University of Hong Kong (HKU) have reported initial success with chimeric antigen receptor (CAR) T-cell therapy, treating the first patient in Hong Kong in May 2020 in a global lymphoma trial and another leukaemia patient in October 2020 in a real-world clinical practice setting.
